Marlee Muilenburg

Calcineurin and mTOR Inhibitor-Free Post-Transplantation Cyclophosphamide and Bortezomib Combination for Graft-versus-Host Disease Prevention after Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I/II Study.

U. Duffner, J. Parker, M. Abidi, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either Agent Alone.

Yuxin Feng, M. Mclane, A. Al-Homsi, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bortezomib for the prevention and treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Yuxin Feng, U. Duffner, A. Abdel-Mageed, 2016, Experimental hematology.

Ixazomib suppresses human dendritic cell and modulates murine graft-versus-host disease in a schedule-dependent fashion.

Yuxin Feng, M. Mclane, A. Al-Homsi, 2017, Experimental hematology.